Oncotarget

Research Papers:

Genomic copy number gains of ErbB family members predict poor clinical outcomes in glioma patients

Rui Liu, Yiping Qu, Lihong Chen, Jun Pu, Sharui Ma, Xiaozhi Zhang, Qi Yang, Bingyin Shi, Peng Hou and Meiju Ji _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:92275-92288. https://doi.org/10.18632/oncotarget.21228

Metrics: PDF 1282 views  |   HTML 1946 views  |   ?  


Abstract

Rui Liu1,2, Yiping Qu1, Lihong Chen3, Jun Pu1, Sharui Ma1, Xiaozhi Zhang2, Qi Yang1, Bingyin Shi1,4, Peng Hou1,4 and Meiju Ji5

1Department of Endocrinology, The First Affiliated Hospital of Xi’an Jiaotong University School of Medicine, Xi’an 710061, P. R. China

2Department of Radio-Oncology, The First Affiliated Hospital of Xi’an Jiaotong University School of Medicine, Xi’an 710061, P. R. China

3Department of Critical Care Medicine, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, P. R. China

4Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, P. R. China

5Center for Translational Medicine, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, P.R. China

Correspondence to:

Meiju Ji, email: [email protected]

Peng Hou, email: [email protected]

Keywords: glioma, ErbB family, copy number gain, clinical outcomes

Received: April 05, 2017     Accepted: August 17, 2017     Published: September 23, 2017

ABSTRACT

The aim of this study was to investigate copy number of ErbB family members (including EGFR, HER2, HER3 and HER4) in a cohort of gliomas and benign meningiomas (control subjects), and explore the associations of their copy number with clinicopathological characteristics and clinical outcomes of glioma patients. Using real-time quantitative PCR assay, we demonstrated that copy number of EGFR, HER2, HER3 and HER4 in glioma patients was significantly increased compared to control subjects. Moreover, our data also showed that the risk of cancer-related death was positively associated with copy number gain (CNG) of EGFR, HER3 and HER4, but not HER2. CNG of EGFR and HER2 was positively related to radiotherapy, while CNG of HER3 and HER4 was negatively related to chemotherapy. Importantly, EGFR CNG significantly shortened median survival times of glioma patients regardless of gender, tumor grade and therapeutic regimens. Stratified analysis showed that CNG of HER2-4 almost did not influence the survival of male patients, patients with high-grade tumors and patients receiving chemotherapy, but dramatically shortened median survival times of female patients, those with low-grade tumors and those receiving radiotherapy. Collectively, our data not only demonstrate that the members of ErbB family are frequently amplified in gliomas, but also suggest that these common genetic events may be prognostic factors for poor clinical outcomes in glioma patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21228